Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2009.

Total revenue for the second quarter of 2009 was $3.5 million, with a net loss of $22.9 million, including non-cash charges of $21.0 million related to the financing completed in April. Loss from operations was $1.9 million for the second quarter and $10.2 million for the first half of 2009. As of June 30, 2009, cash, cash equivalents and marketable securities totaled $7.3 million, with no debt outstanding.

"In the second quarter, we completed the initial closing of a tranched financing of up to $43.5 million with a syndicate of experienced life science investors. We also presented positive new data on all three of our Phase 2 voreloxin studies at ASCO," said Daniel Swisher, Chief Executive Officer of Sunesis. "As we finish enrollment of both of our Phase 2 studies in AML, we are actively planning for an End-of-Phase 2 meeting later this year with the FDA to gain concurrence on our AML registration strategy."

Recent Highlights

  • In April, Sunesis completed a $10.0 million initial closing of a tranched private placement of up to $43.5 million. The private placement contemplates the sale of up to $15.0 million of units of convertible preferred stock and common stock warrants and up to $28.5 million in common stock to accredited investors, including certain members of management. In the initial closing, $10.0 million of units were sold, resulting in net proceeds of $8.8 million. The remaining units may be issued by Sunesis upon the satisfaction of a clinical milestone and Sunesis' common stock trading above a specified floor price or upon approval by a majority
    '/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... While administrative claims and other data ... a relatively long period of time, there has ... of these ‘big data’ for comparisons of interventions ... powerful computer technology with the plethora of data ... significant promise for identifying optimal interventions for specific ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 July ... (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication ... E. Hogan, Ph.D. Vice President of Life Sciences, a ... , Dr. Hogan will lead APDN’s drive ... business relationships with biotech and healthcare customers, provide guidance ...
(Date:7/30/2014)... JUPITER, Fla. , July 30, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... enzymes and other proteins for the bioenergy, bio-based ... the appointment of Thomas "Tom" Dubinski as Vice ... responsible for leading the financial and information technology ...
(Date:7/30/2014)... IL (PRWEB) July 30, 2014 ... Arun Athmanathan will present his findings on corn ... Energy conference this week in Washington, D.C. ... of Energy conference is a testament to the ... John Caupert said. “Thanks to the foresight and ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... that allow nanoparticles to assemble themselves into designer materials ... of Iowa State University and the Ames Laboratory reports ... Science . Travesset, an associate professor of physics ... of Energy,s Ames Laboratory, writes in the journal,s Perspectives ...
... today announced that Jeff Liter has been appointed as ... "Jeff,s diverse background in all aspects of corporate development ... Said Matt McManus, President and CEO, PrimeraDx.  "PrimeraDx,s strategy ... Plex system in the MDx market and define ...
... from the Faculty of Biology and Biotechnology at the ... of Biological Chemistry explaining why enzymes used for ... In collaboration with researchers from Berlin, they used spectroscopic ... that lead to the inactivation of the enzyme,s iron ...
Cached Biology Technology:Iowa State, Ames Lab physicist says nanoparticle assembly is like building with LEGOs 2PrimeraDx Appoints Jeff Liter as VP of Corporate Development 2If oxygen becomes the undoing of proteins 2
(Date:7/29/2014)... climate warms and sea ice retreats, the North is ... increasingly open water which is predicted to extend across ... century. Storms thus have the potential to create Arctic ... and unpredictable element to the region. , A University of ... the middle of the Arctic Ocean, and detected house-sized ...
(Date:7/29/2014)... journey to the edge of science, Clment Vidal takes ... Beginning and the End: Does our universe have a ... we alone in the universe? What is the role ... in science and committed to philosophical rigor, the book ... life is not an accident, but may well be ...
(Date:7/29/2014)... have developed an easier method to create DNAprotein ... involved in diagnosing diseases. , DNA linked to ... partnership that can be used in diagnostic techniques, ... tag proteins with DNA can be used ... visualisation of biological material. The method also provides ...
Breaking Biology News(10 mins):Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3Book: 'The Beginning and the End' 2New method provides researchers with efficient tool for tagging proteins 2
... in the FASEB Journal ( http://www.fasebj.org ) ... because scientists have moved closer toward correcting the root ... Specifically researchers identified a protein (G6PD protein) and its ... promote the growth of cells which produce and release ...
... pregnant and looking for an excuse to eat bacon and eggs, ... January 2010 print issue of the FASEB Journal ( ... shows that choline plays a critical role in helping fetal brains ... pork, as well as chicken eggs. "Our study in ...
... 2010) Autism Speaks applauds the consensus statement and ... (GI) disorders in children with autism spectrum disorders (ASD) ... in advancing physician awareness of unique challenges in the ... to see the publication of these consensus recommendations. Autism ...
Cached Biology News:New discovery by Harvard scientists aims to correct cellular defects leading to diabetes 2Finally, an excuse for pregnant women to eat bacon and eggs 2Pediatrics GI recommendations -- first step to guidelines for children with autism 2Pediatrics GI recommendations -- first step to guidelines for children with autism 3
Request Info...
Immunogen: Recombinant full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
... Immunogen: Synthetic peptide derived from the ... bovine Math-2. Specificity: Specific for ... Rat (positive controls: human U251 A172 ... and rat brain homogenates)Storage: Store at ...
Biology Products: